PE20110330A1 - Composicion topica para el tratamiento de queratosis actinica - Google Patents
Composicion topica para el tratamiento de queratosis actinicaInfo
- Publication number
- PE20110330A1 PE20110330A1 PE2010001215A PE2010001215A PE20110330A1 PE 20110330 A1 PE20110330 A1 PE 20110330A1 PE 2010001215 A PE2010001215 A PE 2010001215A PE 2010001215 A PE2010001215 A PE 2010001215A PE 20110330 A1 PE20110330 A1 PE 20110330A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- treatment
- group
- actinic keratosis
- same
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 208000009621 actinic keratosis Diseases 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title 1
- 150000001298 alcohols Chemical class 0.000 abstract 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 2
- -1 CARBOXYL ACIDS Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 229920002678 cellulose Chemical class 0.000 abstract 1
- 239000001913 cellulose Chemical class 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 229920001519 homopolymer Polymers 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 102000027483 retinoid hormone receptors Human genes 0.000 abstract 1
- 108091008679 retinoid hormone receptors Proteins 0.000 abstract 1
- 229960004889 salicylic acid Drugs 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical class C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
SE REFIERE A UNA COMPOSICION DE GEL TOPICA QUE COMPRENDE A) UN AGENTE ACTIVO PARA EL TRATAMIENTO DE LA QUERATOSIS ACTINICA QUE COMPRENDE 0,25 Y 4,5% EN PESO SELECCIONADO DEL GRUPO DE INHIBIDORES DE CICLOOXIGENASA, MODULADORES INMUNOLOGICOS TOPICOS, ANTIMETABOLITOS Y MEZCLAS DE LO MISMOS; B) UN AGENTE QUERATOLITICAMENTE ACTIVO QUE COMPRENDE ENTRE 0,025 Y 30% EN PESO SELECCIONADO ENTRE AGONISTAS DEL RECEPTOR RETINOIDE, UREA, ACIDOS ORGANICOS TALES COMO ACIDO GLICOLICO, ACIDO SALICILICO, ACIDO LACTICO, ENTRE OTROS, Y MEZCLAS DE LOS MISMOS; C) UN FORMADOR DE GEL QUE COMPRENDE ENTRE 1 Y 30% EN PESO SELECCIONADO DE HOMOPOLIMEROS Y COPOLIMEROS DE VINILO, DERIVADOS DE CELULOSA Y MEZCLAS DE LOS MISMOS; D) UN SOVENTE ORGANICO QUE COMPRENDE ENTRE 1 Y 90% EN PESO SELECCIONADO DEL GRUPO DE ALCOHOLES C1-C10, ESTERES DE ALCOHOLES C1-C10 CON ACIDOS CARBOXILICOS C1-C10 Y MEZCLAS DE LOS MISMOS. ADEMAS PUEDE CONTENER UN MEJORADOR DE PENETRACION DE LA PIEL SELECCIONADO DEL GRUPO DE ALCOHOLES POLIVALENTES ALIFATICOS C2-C10, POLIALQUILENGLICOLES, ETERES NO ALCOXILADOS, ENTRE OTROS. DICHA COMPOSICION COMPRENDE MENOS QUE UN 5% EN PESO DE AGUA, TIENE UNA VISCOSIDAD ENTRE 300 A 1500 mPas A 20ºC, UTIL EN EL TRATAMIENTO DE QUERATOSIS ACTINICA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08012237A EP2143421A1 (en) | 2008-07-07 | 2008-07-07 | Topical composition for the treatment of actinic keratosis |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110330A1 true PE20110330A1 (es) | 2011-06-11 |
Family
ID=40039993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010001215A PE20110330A1 (es) | 2008-07-07 | 2009-06-29 | Composicion topica para el tratamiento de queratosis actinica |
Country Status (32)
Country | Link |
---|---|
US (1) | US8569320B2 (es) |
EP (2) | EP2143421A1 (es) |
JP (2) | JP5654987B2 (es) |
KR (1) | KR101689898B1 (es) |
CN (2) | CN104825384A (es) |
AR (1) | AR072685A1 (es) |
AU (1) | AU2009267471B2 (es) |
BR (1) | BRPI0915439B8 (es) |
CA (1) | CA2729974A1 (es) |
CL (1) | CL2010001642A1 (es) |
CO (1) | CO6351710A2 (es) |
CY (1) | CY1116111T1 (es) |
DK (1) | DK2315581T3 (es) |
EA (1) | EA019533B1 (es) |
EC (1) | ECSP11010762A (es) |
ES (1) | ES2532948T3 (es) |
HK (1) | HK1154793A1 (es) |
HR (1) | HRP20150222T1 (es) |
IL (1) | IL210134A (es) |
ME (1) | ME02147B (es) |
MX (1) | MX2011000054A (es) |
MY (1) | MY158428A (es) |
NZ (1) | NZ590288A (es) |
PE (1) | PE20110330A1 (es) |
PL (1) | PL2315581T3 (es) |
PT (1) | PT2315581E (es) |
RS (1) | RS53887B1 (es) |
SI (1) | SI2315581T1 (es) |
TW (1) | TWI433692B (es) |
UA (1) | UA101044C2 (es) |
WO (1) | WO2010003568A1 (es) |
ZA (1) | ZA201100653B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101791705B1 (ko) * | 2009-10-08 | 2017-10-30 | 바이엘 컨수머 케어 악티엔게젤샤프트 | 저 에테르 조성물 및 전달 장치 |
JP5950528B2 (ja) * | 2011-09-30 | 2016-07-13 | 小林製薬株式会社 | 皮膜形成性外用製剤 |
AU2012324031B2 (en) * | 2011-12-12 | 2015-10-08 | Leo Laboratories Limited | Gel compositions |
NZ606177A (en) * | 2012-01-30 | 2014-03-28 | Dolorgiet Gmbh & Co Kg | Compositions for the treatment of actinic keratosis |
GB201222405D0 (en) * | 2012-12-12 | 2013-01-23 | Leo Lab Ltd | Gel compositions |
CA2956831A1 (en) | 2014-07-31 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
EP3967312A1 (en) | 2014-09-12 | 2022-03-16 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
JP6659735B2 (ja) | 2015-07-10 | 2020-03-04 | インフェクトファーム・アルツナイミッテル・ウント・コンシリウム・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 日光角化症の治療における水酸化カリウムの使用 |
GB201604484D0 (en) * | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
AU2018231144B2 (en) | 2017-03-10 | 2023-12-21 | Atnx Spv, Llc | Methods of treating and/or preventing actinic keratosis |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
US20220175769A1 (en) * | 2020-12-08 | 2022-06-09 | Ankh Life Sciences Limited | Method of treatment of actinic keratoses |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2802005A (en) | 1957-08-06 | S-eluorourace | ||
US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US5167649A (en) * | 1988-08-22 | 1992-12-01 | Zook Gerald P | Drug delivery system for the removal of dermal lesions |
US5093360A (en) * | 1989-04-07 | 1992-03-03 | Yu Ruey J | Retinal, derivatives and their therapeutic use |
GB9023701D0 (en) * | 1990-10-31 | 1990-12-12 | Efamol Holdings | Medical treatment |
JP3117502B2 (ja) * | 1991-08-27 | 2000-12-18 | 株式会社資生堂 | 皮膚外用剤 |
US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
EP1210937A3 (en) * | 1996-06-20 | 2003-02-05 | Lavipharm S.A. | Device for topical treatment of acne and its method of manufacture |
US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
US5955097A (en) * | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
ES2223277B1 (es) * | 2003-06-19 | 2006-03-01 | Fernando Bouffard Fita | Composicion anestesica para administracion topica. |
JP2007503428A (ja) * | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー. | 浸透性医薬発泡剤 |
US20050137164A1 (en) * | 2003-09-22 | 2005-06-23 | Moshe Arkin | Diclofenac compositions for the treatment of skin disorders |
AU2005267396B2 (en) * | 2004-06-24 | 2009-09-17 | Idexx Laboratories, Inc. | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
US20070053984A1 (en) | 2005-03-03 | 2007-03-08 | Monique Spann-Wade | Topical gels compositions |
RS50693B (sr) * | 2005-06-14 | 2010-06-30 | Uni-Pharma Kleon Tsetis Pharmaceutical | Stabilni farmaceutski gel diklofenak natrijuma |
US7851431B2 (en) * | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
US20070264317A1 (en) * | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
WO2008047857A1 (fr) * | 2006-10-18 | 2008-04-24 | Fujifilm Corporation | Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé |
-
2008
- 2008-07-07 EP EP08012237A patent/EP2143421A1/en not_active Withdrawn
-
2009
- 2009-06-29 NZ NZ590288A patent/NZ590288A/xx unknown
- 2009-06-29 AU AU2009267471A patent/AU2009267471B2/en active Active
- 2009-06-29 EA EA201100020A patent/EA019533B1/ru unknown
- 2009-06-29 CN CN201510185320.3A patent/CN104825384A/zh active Pending
- 2009-06-29 BR BRPI0915439A patent/BRPI0915439B8/pt active IP Right Grant
- 2009-06-29 ES ES09776876.6T patent/ES2532948T3/es active Active
- 2009-06-29 MY MYPI2011000028A patent/MY158428A/en unknown
- 2009-06-29 UA UAA201101405A patent/UA101044C2/ru unknown
- 2009-06-29 DK DK09776876T patent/DK2315581T3/en active
- 2009-06-29 US US13/002,971 patent/US8569320B2/en active Active
- 2009-06-29 PE PE2010001215A patent/PE20110330A1/es not_active Application Discontinuation
- 2009-06-29 EP EP09776876.6A patent/EP2315581B1/en active Active
- 2009-06-29 PL PL09776876T patent/PL2315581T3/pl unknown
- 2009-06-29 CA CA2729974A patent/CA2729974A1/en not_active Abandoned
- 2009-06-29 MX MX2011000054A patent/MX2011000054A/es active IP Right Grant
- 2009-06-29 KR KR1020117002825A patent/KR101689898B1/ko active IP Right Grant
- 2009-06-29 SI SI200931142T patent/SI2315581T1/sl unknown
- 2009-06-29 WO PCT/EP2009/004682 patent/WO2010003568A1/en active Application Filing
- 2009-06-29 ME MEP-2015-38A patent/ME02147B/me unknown
- 2009-06-29 JP JP2011516999A patent/JP5654987B2/ja active Active
- 2009-06-29 RS RS20150185A patent/RS53887B1/en unknown
- 2009-06-29 CN CN2009801266635A patent/CN102088957A/zh active Pending
- 2009-06-29 PT PT97768766T patent/PT2315581E/pt unknown
- 2009-07-03 AR ARP090102493A patent/AR072685A1/es unknown
- 2009-07-06 TW TW098122756A patent/TWI433692B/zh active
-
2010
- 2010-12-20 IL IL210134A patent/IL210134A/en active IP Right Grant
- 2010-12-30 CL CL2010001642A patent/CL2010001642A1/es unknown
-
2011
- 2011-01-17 EC ECSP11010762 patent/ECSP11010762A/es unknown
- 2011-01-26 ZA ZA2011/00653A patent/ZA201100653B/en unknown
- 2011-02-07 CO CO11013458A patent/CO6351710A2/es not_active Application Discontinuation
- 2011-08-29 HK HK11109094.3A patent/HK1154793A1/xx unknown
-
2014
- 2014-10-16 JP JP2014211989A patent/JP2015038129A/ja not_active Withdrawn
-
2015
- 2015-02-26 HR HRP20150222TT patent/HRP20150222T1/hr unknown
- 2015-03-13 CY CY20151100254T patent/CY1116111T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110330A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
PE20140936A1 (es) | Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas | |
BR112013018352A2 (pt) | composição de minociclina tópica e método | |
PE20150200A1 (es) | Formulacion de anticuerpos | |
ES2580635T3 (es) | Composición cosmética que comprende un agente estructurante, un agente absorbente y un agente tensioactivo para la aplicación a las materias queratínicas | |
CL2015001984A1 (es) | (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. | |
MX2018011881A (es) | Sistema de administracion. | |
PE20091363A1 (es) | Gel de quitosano y proceso de obtencion | |
ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
BR112014016550A8 (pt) | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma | |
PE20081406A1 (es) | Composiciones farmaceuticas de flunixina | |
BR112014016661A8 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
PE20121709A1 (es) | Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica | |
AR067751A1 (es) | Composicion veterinaria topica, proceso para la preparacion de una composicion y metodo para el tratamiento de infeccion endoparasitaria o infestacion en un animal homeotermico | |
JP2015512926A5 (es) | ||
PE20170691A1 (es) | Composiciones farmaceuticas de accion prolongada | |
AR083651A1 (es) | Composiciones de brimonidina en gel y metodos de uso | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
BR112017017643A2 (pt) | formulação farmacêutica tópica | |
MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. | |
NI201500007A (es) | Formulación transdérmica que contiene inhibidores de cox | |
PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
PE20160198A1 (es) | Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |